

1 **Genome-wide association study of prostate-specific antigen levels in 392,522 men**
2 **identifies new loci and improves cross-ancestry prediction**

3
4 Thomas J Hoffmann^{1,2,*}, Rebecca E Graff^{2,*}, Ravi K Madduri³, Alex A Rodriguez³, Clinton L
5 Cario⁴, Karen Feng⁵, Yu Jiang^{2,4}, Anqi Wang^{6,7}, Robert J Klein⁸, Brandon L Pierce^{9,10,11}, Scott
6 Eggener^{12,11,13}, Lin Tong⁹, William Blot¹⁴, Jirong Long¹⁴, Louisa B Goss¹⁵, Burcu F Darst¹⁵,
7 Timothy Rebbeck¹⁶, Joseph Lachance¹⁷, Caroline Andrews¹⁶, Akindede O Adebisi¹⁸, Ben
8 Adusei¹⁹, Oseremen I Aisuodionoe-Shadrach²⁰, Pedro W Fernandez²¹, Mohamed Jalloh²²,
9 Rohini Janivara¹⁷, Wenlong C Chen²³, James E Mensah²⁴, Ilir Agalliu²⁵, Sonja I Berndt²⁶, John P
10 Shelley²⁷, Kerry Schaffer²⁸, Mitchell J Machiela²⁶, Neal D Freedman²⁶, Wen-Yi Huang²⁶,
11 Shengchao A Li²⁶, Phyllis J Goodman²⁹, Cathee Till²⁹, Ian Thompson³⁰, Hans Lilja^{31,32}, Dilrini K
12 Ranatunga³³, Joseph Presti³⁴, Stephen K Van Den Eeden³⁴, Stephen J Chanock²⁶, Jonathan D
13 Mosley^{35,27}, David V Conti^{6,7}, Christopher A Haiman^{6,7}, Amy C Justice^{36,37}, Linda Kachuri^{4,38,**},
14 John S Witte^{4,38,5,39,**}

- 15 1. Institute for Human Genetics, University of California San Francisco, San Francisco, CA,
16 USA
17 2. Department of Epidemiology and Biostatistics, University of California San Francisco,
18 San Francisco, CA, USA
19 3. Data Science and Learning Division, Argonne National Laboratory, Argonne, IL, USA
20 4. Department of Epidemiology and Population Health, Stanford University School of
21 Medicine, Stanford, CA, USA
22 5. Department of Biomedical Data Science, Stanford University, Stanford, CA, USA
23 6. Center for Genetic Epidemiology, Department of Population and Preventive Health
24 Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA,
25 USA
26 7. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern
27 California, Los Angeles, CA, USA
28 8. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
29 Sinai, New York, NY, USA
30 9. Department of Public Health Sciences, University of Chicago, Chicago, IL, USA
31 10. Department of Human Genetics, University of Chicago, Chicago, IL, USA
32 11. Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA
33 12. Department of Urology, University of Chicago, Chicago, IL, USA
34 13. Department of Surgery, University of Chicago, Chicago, IL, USA
35 14. Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA
36 15. Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
37 16. Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
38 17. School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
39 18. Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan,
40 Nigeria
41 19. 37 Military Hospital, Accra, Ghana

- 42 20. College of Health Sciences, University of Abuja, Abuja, Nigeria; Cancer Science Centre
43 Abuja, Abuja, Nigeria; University of Abuja Teaching Hospital, Abuja, Nigeria
44 21. Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South
45 Africa
46 22. Hospital General Idrissa Pouye, Dakar, Senegal; Ecole Doctorale, Univesite Iba Der
47 Thiam de Thies
48 23. Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University
49 of the Witwatersrand, Johannesburg, South Africa; Sydney Brenner Institute for
50 Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand,
51 Johannesburg, South Africa; National Cancer Registry, National Institute for
52 Communicable Diseases a Division of the National Health Laboratory Service,
53 Johannesburg, South Africa
54 24. Korle-Bu Teaching Hospital and University of Ghana Medical School, Accra, Ghana
55 25. Dept of Epidemiology and Population Health, and Dept of Urology, Albert Einstein
56 College of Medicine, New York, NY, USA
57 26. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD,
58 USA
59 27. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville,
60 TN, USA
61 28. Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville,
62 TN, USA
63 29. SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research
64 Center, Seattle, WA, USA
65 30. CHRISTUS Santa Rosa Medical Center Hospital, San Antonio, TX, USA
66 31. Departments of Pathology and Laboratory Medicine, Surgery, Medicine, Memorial Sloan
67 Kettering Cancer Center, New York, NY, USA
68 32. Department of Translational Medicine, Lund University, Malmö, Sweden
69 33. Kaiser Permanente Research Bank, Oakland, CA, USA
70 34. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
71 35. Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN,
72 USA
73 36. Veterans Administration Connecticut Healthcare System, West Haven, Connecticut,
74 USA
75 37. Department of Internal Medicine and Yale University School of Public Health, Yale
76 School of Medicine, New Haven, Connecticut, USA
77 38. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
78 39. Department of Genetics (by courtesy), Stanford University, Stanford, CA, USA

79 *These authors contributed equally to this work.

80 **These authors jointly supervised this work.

81 Correspondence should be addressed to: J.S.W. (jswitte@stanford.edu) and L.K.

82 (lkachuri@stanford.edu)

83

84

85 **Abstract**

86 We conducted a multi-ancestry genome-wide association study of prostate-specific antigen
87 (PSA) levels in 296,754 men (211,342 European ancestry; 58,236 African ancestry; 23,546
88 Hispanic/Latino; 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran
89 Program). We identified 318 independent genome-wide significant ($p \leq 5e-8$) variants, 184 of
90 which were novel. Most demonstrated evidence of replication in an independent cohort
91 ($n=95,768$). Meta-analyzing discovery and replication ($n=392,522$) identified 447 variants, of
92 which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide
93 polygenic risk scores ranged from 11.6%-16.6% in European ancestry, 5.5%-9.5% in African
94 ancestry, 13.5%-18.2% in Hispanic/Latino, and 8.6%-15.3% in Asian ancestry, and decreased
95 with increasing age. Mid-life genetically-adjusted PSA levels were more strongly associated with
96 overall and aggressive prostate cancer than unadjusted PSA. Our study highlights how
97 including proportionally more participants from underrepresented populations improves genetic
98 prediction of PSA levels, offering potential to personalize prostate cancer screening.
99

100 Introduction

101 Prostate-specific antigen (PSA) is a protein encoded by the *KLK3* gene and secreted by the
102 prostate gland¹⁻³. PSA levels are often elevated in those with prostate cancer (PCa); however,
103 elevated levels can also be caused by other factors, such as benign prostatic hyperplasia
104 (BPH), local inflammation or infection, prostate volume, age, and germline genetics⁴⁻⁸. PSA
105 screening for PCa was approved by the Food and Drug Administration in 1994, but it is unclear
106 if the benefits for PCa-specific mortality reduction outweigh the harms from overdiagnosis and
107 treatment of clinically insignificant disease⁹⁻¹². Previous work estimates 20-60% of screen-
108 detected PCas are overdiagnoses (i.e., PCa that would not otherwise clinically manifest, or
109 result in PCa-related death¹³), other work has suggested that 229 individuals would need to be
110 invited to screen and 9 would need to be diagnosed to prevent one death¹⁴, and the United
111 States¹⁵, Canada¹⁶, and the United Kingdom¹⁷ recommend against universal population-based
112 screening. If PSA levels could be adjusted for an individual's predisposition in the absence of
113 PCa, the specificity (to reduce overdiagnosis) and sensitivity (to prevent more deaths) of
114 screening could be improved.

115
116 Twin studies estimate PSA heritability at 40-45%^{18,19}, and genome-wide heritability estimates at
117 25%-30%²⁰ suggesting that incorporating genetic factors may improve screening. Recent work
118 from our group based on 85,824 European ancestry and 9,944 non-European ancestry men
119 found that genetically-adjusted PSA (i.e., the PSA measure inflated or deflated due to an
120 individual's genetic variants) most improved the discrimination of PSA screening for aggressive
121 tumors²⁰. In that work, we identified 128 genome-wide significant variants that explained up to
122 7% of PSA variation in European ancestry, suggesting that many more PSA loci remain.
123 Genome-wide polygenic risk scores (PRSs) explained up to 10% in European ancestry;
124 however, the PRSs were less predictive in other groups, especially African ancestry (1-3%).
125 Additional variant discovery with larger, more diverse cohorts could provide novel insights into
126 the genetic architecture of PSA and further improve PCa screening.

127 Results

128 **Composition of discovery and replication cohorts**

129 Our discovery population consisted of 296,754 men without PCa from 9 cohorts: 211,342
130 European ancestry (71.2%), 58,236 African ancestry (19.6%), 23,546 Hispanic/Latino (7.9%),
131 and 3,630 Asian ancestry (1.2%). None had been included in previous PSA GWASs. We
132 present genotype platform details in **Table S1**, demographics in **Table S2**, and quality control
133 (QC) metrics in **Table S3**. The pooled mean age at PSA measurement across the discovery
134 cohorts was 57.4 (standard deviation [SD]=9.6), and the pooled median PSA was 0.84. The
135 Million Veteran Program (MVP) comprised 96.5% of the discovery cohort. For replication, we
136 utilized results from 95,768 independent individuals from previous work²⁰, including 85,824
137 European ancestry, 3,509 African ancestry, 3,098 Hispanic/Latino, and 3,337 Asian ancestry
138 individuals (**Table S3**). **Figure 1** summarizes our analytical workflow and describes cohort
139 ancestry compositions.

140 **Discovery GWAS analysis of PSA-associated variants**

143 In our discovery cohorts, we identified 318 independent genome-wide significant variants (264
144 European, 51 African, 17 Hispanic/Latino, and 2 Asian) in a multi-ancestry analysis of log-
145 transformed PSA levels (**Figure 2, Figure S1, Table S4, Table S5**) that used multiple reference
146 panels to account for different ancestries (see **Methods**). Among them, 184 independent
147 variants selected by mJAM²¹ were novel (see **Methods**). Of the novel variants, 57 replicated at
148 a Bonferroni level ($p < 0.05/184 = 0.00027$, same direction of effect on PSA), an additional 80
149 replicated at $p < 0.05$ (and the same direction), 43 demonstrated the same effect direction (but
150 $p > 0.05$), and four showed no indication of replication (effect in the opposite direction). On
151 average, compared to the non-replicated variants, the replicated variants had slightly larger
152 effect sizes (mean $\beta = 0.30$ versus 0.27) and were slightly more precise (mean standard
153 error = 0.0039 versus 0.0042).

154
155 Of the 184 variants that were novel in the multi-ancestry analysis, 112 were genome-wide
156 significant in the European ancestry discovery cohort, eight were genome-wide significant in the
157 African ancestry cohort, and none were genome-wide significant in Asian or Hispanics/Latino
158 individuals (likely due to low sample size; **Figure S2**). Of the eight in African ancestry
159 individuals, only two variants were frequent enough (see **Methods**) to be assessed in other
160 ancestry groups: rs2071041 (*ITIH4*; $\beta_{\text{African}} = 0.0237$, 95% CI = 0.0152-0.0322, $p_{\text{African}} = 4.9e-8$) that
161 was also genome-wide significant in European ancestry individuals ($\beta_{\text{European}} = 0.0180$, 95%
162 CI = 0.0124 to 0.0235, $p_{\text{European}} = 2.6e-10$, minor allele frequency (MAF) = 23.7%), and rs1203888
163 (*LINC00261*; $\beta_{\text{African}} = -0.0423$, 95% CI = -0.0539 to -0.0307, $p_{\text{African}} = 8.7e-13$) that was not
164 significant in European ancestry individuals ($p > .05$, MAF = 0.8%). The latter variant showed
165 similar magnitude of effect but was not Bonferroni significant in discovery Hispanic/Latino
166 individuals ($\beta_{\text{Hispanic/Latino}} = -0.0748$, 95% CI = -0.120 to -0.0297, $p_{\text{Hispanic/Latino}} = 0.0012$, MAF = 3.1%)
167 and was not significant in discovery Asian ancestry ($p > .05$, MAF = 3.5%) or the replication
168 cohorts ($p > .05$) (**Table S4**). The remaining six African ancestry variants were too rare to be
169 assessed in European ancestry individuals. The variant rs184476359 (*AR*, multi-ancestry
170 discovery $\beta = -0.0590$, 95% CI = -0.0774 to -0.0406, $p = 3.4e-10$; replication $\beta = -0.0870$, 95% CI =
171 0.1370 to -0.0371, $p = 6.3e-4$) was common in African ancestry individuals (MAF = 17.7%), less
172 common in Hispanic/Latinos (MAF = 1.1%), and not adequately polymorphic to be imputed in
173 Asian individuals. Three variants in genes that encode PSA (rs76151346, $\beta_{\text{African}} = 0.0821$, 95%
174 CI = 0.0577 to 0.107, $p_{\text{African}} = 4.6e-11$, *KLK3*; rs145428838, $\beta_{\text{African}} = 0.224$, 95% CI = 0.165 to 0.284,
175 $p_{\text{African}} = 1.4e-13$, *KLK3*; rs182464120 $\beta_{\text{African}} = -0.213$, 95% CI = 0.278 to 0.147, $p_{\text{African}} = 2.0e-10$,
176 *KLK2*) exclusively imputed in African ancestry individuals (all MAF < 5%, two < 1%) did not exhibit
177 strong evidence of replication in African ancestry individuals ($p > 0.05$). The remaining two
178 variants identified in African ancestry (rs7125654, $\beta_{\text{African}} = -0.384$, 95% CI = -0.0489 to -0.0279,
179 $p_{\text{African}} = 7.0e-13$; rs4542679, $\beta_{\text{African}} = 0.0422$, 95% CI = 0.0288 to 0.0557, $p_{\text{African}} = 7.9e-10$), were
180 more common (MAF > 5%) but also did not replicate ($p > 0.05$). Further, rs7125654 (*TRPC6*) was
181 less common in Latinos, but more common in Asian ancestry, and rs4542679 (*RP11-345M22.3*)
182 was less common in Latinos and not adequately polymorphic in Asians.

183
184 We next tested for effect size differences across ancestry groups for the 184 novel variants.
185 Only one variant, rs12700027 (*BRAT1/LFNG*, $I^2 = 84.8$, $p = 0.00019$), demonstrated heterogeneity

186 that was Bonferroni-significant ($p < 0.05/184 = 0.00027$). The variant had a strong discovery effect
187 in European ancestry individuals ($\beta = 0.0327$, 95% CI = 0.0247 to 0.0407, $p = 1.2e-15$, MAF = 0.10),
188 but was not significant in other groups (African ancestry $\beta = 0.0131$, 95% CI = -0.0190 to 0.0452,
189 $p = 0.42$, MAF = 0.021; Asian $\beta = -0.176$, 95% CI = -0.0203 to 0.0797, $p = 0.027$, MAF = 0.021;
190 Hispanic/Latino $\beta = -0.0102$, 95% CI = -0.0326 to 0.0121, $p = 0.37$, MAF = 0.120). In our replication
191 cohort, the variant nominally (i.e., $p < 0.05$) replicated ($p = 0.0065$, $\beta = 0.0175$, 95% CI = 0.00491 to
192 0.0302; European ancestry $p = 0.003$, $\beta = 0.0327$, 95% CI = 0.0247 to 0.0407) and showed no
193 statistically significant evidence of differences across ancestry groups ($I^2 = 0.0$, $p = 0.44$), although
194 sample sizes for detecting differences were smaller.

195
196 In-silico assessment of potential functional features revealed that 20 of the novel variants
197 (10.8%) were prostate tissue expression quantitative trait loci (eQTLs), and another 65 (35.3%)
198 were eQTLs in other tissues (**Table S4**). Five novel variants were missense and predicted to be
199 deleterious, with Combined Annotation Dependent Depletion (CADD) scores > 20 (**Table S4**):
200 rs11556924 in *ZC3HC1*, which regulates cell division onset; rs74920406 in *ELAPOR1*, a
201 transmembrane protein; rs2229774 in *RARG*, a gene in the hormone receptor family;
202 rs113993960 ($\Delta 508$) in *CFTR*, a causal mutation for cystic fibrosis²²; and rs2991716 upstream
203 of LOC101927871. An additional 11 variants were predicted to have high pathogenicity (CADD
204 scores > 15 ; **Table S4**).

205 206 **Replication analysis of previously-reported variants in the discovery cohort**

207 When we tested 128 previously identified variants²⁰ in our discovery cohort, 106 (82.8%)
208 replicated at a genome-wide significance level, an additional 15 replicated (11.7%) at a
209 Bonferroni level ($p < 0.05/128 = 0.00039$), an additional 6 replicated at $p < 0.05$ (4.7%), and one
210 variant flipped effect direction (**Table S6**). Replication was highest for European ancestry, likely
211 due to sample size, with 94 variants (73%) reaching genome-wide significance, an additional 22
212 variants (17.2%) meeting a Bonferroni-corrected level, and 8 (6.3%) additional variants meeting
213 $p < 0.05$ (**Table S6**). Replication rates within African ancestry, our next largest group, were lower:
214 16 (12.5%) were genome-wide significant, 26 others (20.3%) met a Bonferroni level, an
215 additional 39 (30.5%) had $p < 0.05$, 32 additional (25.0%) were in the same direction, and 15
216 (11.7%) were in the opposite direction. Estimated rates were similar for Hispanic/Latino and
217 lowest for Asian populations. Lastly, 16 of the 128 known variants showed heterogeneity across
218 the four groups (Bonferroni corrected $p < 0.05/128 = 0.00039$).

219 220 **Joint meta-analysis of discovery and replication cohorts**

221 In the multi-ancestry analysis including the discovery and replication cohorts, we identified 447
222 independent variants (409 European, 56 African, 22 Hispanic/Latino, 6 Asian, including 46 in > 1
223 group; **Figure 3, S1; Table S7, S8**). Among the 111 variants that were novel even relative to
224 discovery alone, none showed evidence of ancestry effect size differences
225 ($p > 0.05/111 = 0.00045$). Fifty-six (50.4%) of the 111 were genome-wide significant in European
226 ancestry individuals, but none were genome-wide significant in a non-European ancestry group
227 (**Table S8**). Allele frequencies and effect sizes of the novel variants largely followed those
228 expected by power curves (**Figure 4**).

229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271

In the joint meta-analysis, 12 (10.8%) novel variants were prostate tissue eQTLs, and 50 (45.0%) additional were eQTLs for other tissues. Two were missense substitutions (**Table S7**): rs1049742 in *AOC1* and rs74543584 in *MPZL2*. Three additional novel variants had CADD scores > 15: rs1978060, an eQTL for *TBX1* in prostate tissue; rs339331 an eQTL for *FAM162B* in adipose tissue; and rs57580158, an intergenic variant with evidence of conservation.

Medication sensitivity analysis

The UK Biobank (UKB) had medication information available to conduct a sensitivity analysis to see whether excluding individuals taking medications that could affect PSA levels (i.e., 5-alpha reductase inhibitors and testosterone) would impact our results. For PSA-associated variants, our primary results in the UK Biobank (UKB) were highly correlated ($R=0.93$, **Figure S3**) with the sensitivity analyses, suggesting these medications did not impact our results.

Out-of-sample PSA variance explained by PRSs

We evaluated different strategies for constructing PRSs for PSA levels first using results from our discovery cohort (see **Methods**). For testing these PRSs, four cohorts of men without PCa were out-of-sample: Kaiser Permanente's Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort, the Selenium and Vitamin E Cancer Prevention Trial (SELECT),²³ the Prostate Cancer Prevention Trial (PCPT),²⁴ and All of Us (AOU)²⁵.

In GERA, PRS₃₁₈, constructed from the 318 conditionally-independent genome-wide significant variants in the multi-ancestry meta-analysis, generally had higher variance explained when using longitudinal measurements, rather than earliest PSA value, with 13.9% (95% CI=13.1%-14.6%) in European ancestry (n=35,322), 13.1% (95% CI=10.6%-15.6%) in Hispanics/Latinos (n=2,716), 9.3% (95% CI=6.8%-12.0%) in African ancestry (n=1,585), and 9.0% (95% CI=7.0%-11.4%) in East Asian ancestry (n=2,518). The variance explained in the other three cohorts was ~3-6% lower depending on the group (**Table S9**).

Expanding to a genome-wide approach, PRS-CSx (PRS_{CSx-disc}; included more than genome-wide significant variants (1,070,230 SNPs; see **Methods**) and resulted in improved predictive performance. The variance explained increased to 16.6% (95% CI=15.9%-17.5%) in men of European ancestry and 18.2% (95% CI=15.4%-20.8%) in Hispanic/Latino men (**Figure 5A**, **Table S9**). The relative increase was largest in East Asian ancestry, with variance explained reaching 15.3% (95% CI=12.7%-18.1%), and smallest in African ancestry, with variance explained 8.5% (95% CI=6.1%-11.0%).

Second, we developed PRSs for PSA using the results from the joint GWAS meta-analysis (n=392,522), which combined the discovery meta-analysis with previously published results from Kachuri et al²⁰. These scores were validated in PCPT, SELECT, and AOU, but not GERA, which was included in the previously published meta-analysis and was therefore not out-of-sample .

272 For the independent genome-wide significant PRSs, PRS₃₁₈ explained 9.5% (8.8%-10.3%) of
273 variation in baseline PSA levels in SELECT European ancestry (n=22,173), while PRS₄₄₇ (from
274 the 447 conditionally independent genome-wide significant variants identified in the joint meta-
275 analysis) explained 10.9% (10.2%-11.8%) of the variance, which exceeded the 8.5% (95%
276 CI=7.8%-9.2%) variance explained by PRS₁₂₈ (from the 128 independent variants described in
277 our prior GWAS of 95,768 men²⁰). Variance explained in PCPT European ancestry (n=5,725)
278 was slightly lower. In AOU European ancestry (n=11,922), variance explained was slightly
279 higher, with PRS₁₂₈ explaining 8.6% (95% CI=7.7%-9.6%), PRS₃₁₈ explaining 9.6% (95%
280 CI=8.6%-10.6%), and PRS₄₄₇ explaining 11.3% (95% CI 10.2%-12.4%). We did not observe an
281 appreciable change in differences across cohorts after removing individuals with BPH, a
282 condition known to influence PSA levels. However, variance explained was slightly higher in all
283 populations (<0.5% higher), albeit with overlapping CIs (**Table S9**).

284

285 Among SELECT African ancestry (n=1,173), PRS₁₂₈ explained 3.4% (95% CI=1.6%-5.8%),
286 PRS₃₁₈ explained 6.5% (95% CI=4.0%-9.5%), and PRS₄₄₇ explained 7.0% (95% CI=4.5%-
287 10.1%); PRS₄₄₇ more than doubled variance explained by PRS₁₂₈. AOU African ancestry
288 (n=2,471) estimates were 1-2% smaller.

289

290 A genome-wide PRS-CSx (PRS_{CSx-joint}) compared to PRS_{CSx-disc} modestly increased variance
291 explained by roughly 1-1.5% in European ancestry in PCPT (11.6%, 95% CI=10.0%-13.1%),
292 SELECT (13.9%, 95% CI=13.1%-14.9%), and AOU (14.7%, 95% CI=13.5%-16.0%). PRS_{CSx-joint}
293 also improved ~3% upon the previously published PRS from the Kachuri et al.²⁰ paper
294 estimated here to be 8.6% in PCPT and 10.4% in SELECT for PRS-CSx (PRS_{CSx-Kachuri}, **Table**
295 **S9**). Among men of African ancestry in SELECT, PRS_{CSx-joint} showed no improvement (7.2%,
296 95% CI=4.6%-10.0%) over PRS_{CSx-disc}, while variance explained in AOU increased by 0.3%
297 (5.8%, 95% CI=4.1%-7.8%). Notably, PRS_{CSx-joint} yielded a substantial improvement upon the
298 previously published PRS_{CSx-Kachuri} estimates²⁰ of 1.64% in SELECT, although still under half of
299 that in European ancestry.

300

301 In SELECT European ancestry individuals, PRS-CSx explained 13.9% of variation, while PRS₄₄₇
302 explained 10.9% of the variation. Assuming that variation explained is nested between these
303 approaches, we estimate 78.4% (=10.9%/13.9%) of PRS-CSx variation may be explained by
304 PRS₄₄₇. This is expected since information across the different PRSs overlaps, and the initial
305 genome-wide significant SNPs from our large-scale GWAS are the most informative for
306 explaining variation in PSA levels.

307

308 Third, we examined how the variance in PSA levels explained by the PRSs varied by age.
309 These analyses were performed in GERA to have a large enough sample size in each age
310 group and used PRS_{CSx-disc} to provide out-of-sample estimates. The estimated variance
311 explained by the PRSs decreased with increasing age in all GERA ancestry groups, albeit with
312 somewhat wide confidence intervals (**Figure 5B, Table S10**). For example, PRS_{CSx-disc}
313 explained 16.4% (95% CI 14.6%-18.5%) of variation in PSA levels among European ancestry
314 individuals <50y, and this decreased to 8.7% (95% CI 7.0%-10.5%) for men ≥80y.

315
316 Finally, for PRSs constructed from genome-wide significant independent variants, the variance
317 explained when using weights corresponding to effect sizes from the multi-ancestry meta-
318 analysis was almost always equal to or higher than variance explained when using ancestry-
319 specific weights (**Table S10**). This was observed both for the discovery (PRS₃₁₈) and joint meta-
320 analysis (PRS₄₄₇). The few instances where the variance explained was estimated lower almost
321 always had <1% difference and wide confidence intervals around the estimate (i.e., the smallest
322 sample sizes likely had unstable estimates).

323

324 ***Relationship of PSA PRSs with PCa aggressiveness using Gleason score***

325 In GERA, we performed a case-only analysis to examine the association between PSA
326 PRS_{CSx,disc} (the out-of-sample PRSs with the highest variance explained) and Gleason score.
327 Results were consistent with previous work that suggested that screening bias decreases the
328 likelihood of identifying high-grade disease, whereby men with higher PRS values (indicating a
329 genetic predisposition to higher constitutive PSA levels) are more likely to be biopsied, but less
330 likely to have high grade disease²⁰; we found that in European ancestry cases, an SD increase
331 in PRS_{CSx-disc} was inversely associated with Gleason 7 (OR=0.78, 95% CI=0.73-0.84, p=1.2e-
332 13) and ≥8 (OR=0.71, 95% CI=0.64-0.79, p=6.2e-10) compared to Gleason ≤6. Other ancestry
333 groups had similar estimated ORs, though they were not always statistically significant, likely
334 owing to sample size (**Table S11**; e.g., African ancestry Gleason 7 (OR=0.88, 95% CI=0.67-
335 1.17, p=0.39) and ≥8 (OR=0.65, 95% CI=0.43-0.99, p=0.043)).

336

337 ***Impact of genetically-adjusted PSA on prostate biopsy eligibility***

338 We examined how PRS_{CSx,disc} would have changed biopsy recommendations for cases and
339 controls, according to age-specific thresholds in GERA (see **Methods**). In European ancestry
340 individuals who had negative biopsies (i.e., controls, n=2378), 16.0% with unadjusted PSA
341 levels that exceeded age-specific thresholds for biopsy were reclassified to ineligible for biopsy.
342 Among controls with PSA levels that did not indicate biopsy, 2.4% were reclassified to biopsy
343 eligible, resulting in a control net reclassification improvement (NRI) of 13.6% (95% CI=12.2%-
344 15.0%; **Figure 6A, Table S12**). In individuals with positive biopsies (i.e., cases; n=2,358), 3.9%
345 were reclassified to eligible, while 13.1% were reclassified to ineligible, resulting in a case NRI
346 of -9.2% (95% CI=-10.3% to -8.0%). Of cases who became ineligible, 71.1% had Gleason
347 scores ≤7, as compared to 56.5% who remained eligible (although we note that some of these
348 men may have had biopsies for reasons other than their PSA level, such as abnormal digital
349 rectal exam or strong family history). In African ancestry controls (n=110), 16.0% were
350 reclassified to ineligible, while 2.4% were reclassified to eligible, resulting in an NRI of 3.6%
351 (95% CI=0.1% to 7.1%; **Figure 6B**). In African ancestry cases (n=310), 5.2% were reclassified
352 to eligible and 6.8% were reclassified to ineligible, resulting in an NRI of -1.6% (95% CI=3.0% to
353 -0.2%). Other groups are shown in **Figure S4** with details in **Table S12**. We additionally
354 obtained eight years of additional follow up on the 78 controls in all groups now classified as
355 eligible; three were later diagnosed with PCa.

356
357 To assess potential variability in genetic adjustment across PSA levels, we compared measured
358 versus genetically adjusted PSA levels across a range of values in GERA men. Plotting
359 measured versus adjusted PSA indicated consistent relative adjustment on the log scale
360 (**Figure S5**). For example, at a measured PSA of 2.5, 6.5, and 10.0 ng/ml, the genetically
361 adjusted PSA' IQR ranged from 2.6-3.7, 4.6-6.8, and 9.1-12.5, respectively. These results
362 suggest genetic adjustment is applicable to PSA values <20 displayed in the figure, although
363 the implications are most profound around values where clinical decisions are made (e.g., near
364 age-specific PSA thresholds).

365 366 ***Impact of genetically-adjusted PSA on overall and aggressive PCa***

367 Previous work has suggested that midlife PSA predicts lethal PCa²⁶. In GERA European
368 ancestry, genetically-adjusted midlife log PSA had a larger estimated magnitude of association
369 with overall PCa (OR=4.57, 95% CI=4.27-4.88) than measured PSA (OR=4.30, 95% CI=4.04-
370 4.58)), though the CIs overlapped. The difference between associations was even larger for
371 aggressive disease, with OR=3.92 (95% CI=3.54-4.35) for adjusted vs. OR=3.46 (95% CI=3.15-
372 3.81) for measured, though again CIs overlapped. African ancestry showed similar trends, with
373 the genetically-adjusted association with PCa OR=5.85 (95% CI=4.73-7.23) vs. measured
374 OR=4.72 (95% CI=3.56-6.27), and the aggressive genetically-adjusted OR=5.39 (95% CI=3.95-
375 7.35) vs. measured OR=4.72 (3.56-6.27). Estimates in Hispanic/Latino were also similar, but
376 East Asian ancestry showed no difference (**Table S13**). Cross-validated AUC estimates also
377 showed essentially no difference between adjusted and measured PSA, with estimates ranging
378 from 0.7-0.8 in the different groups (**Table S13**).

379 380 ***Associations with previously-reported PCa variants***

381 In our discovery cohort, 20 of our 184 novel PSA-associated variants (10.8%) were genome-
382 wide significantly associated with PCa in the PRACTICAL consortium's European ancestry
383 GWAS²⁷ (**Tables S4, S6**). An additional 19 variants (10.3%) were associated with PCa at a
384 Bonferroni level ($p < 0.05/184 = 0.00027$). With correction for bias related to more frequent
385 screening in men with higher constitutive PSA levels (see Methods)^{20,28}, this count was reduced
386 to 13 (7.0%) significant at the genome-wide level, and an additional 14 (7.6%) at the Bonferroni-
387 corrected level. Out of the 111 novel PSA-associated variants from the meta-analysis, 8 (7.1%)
388 were genome-wide significantly associated with PCa, and an additional 11 (9.8%) were
389 significant at a Bonferroni level ($p < 0.00045$). With bias correction, 5 (4.5%) were genome-wide
390 significant, and an additional 4 (3.6%) were Bonferroni-significant.

391 392 ***Associations with previously reported BPH variants***

393 In our discovery cohort, one variant (rs1379553) was genome-wide significantly associated with
394 BPH out of 137 variants available in a GWAS in UKB European ancestry²⁹. An additional eight
395 met a Bonferroni level ($p < 0.05/137 = 0.00036$). Out of the 96 available variants identified from the
396 meta-analysis, one variant was genome-wide significant (rs627320), and 6 more met a
397 Bonferroni level ($p < 0.045/96 = 0.00052$).

398

399 **Associations with urinary symptom variants**

400 In variants identified in our discovery cohort, rs12573077 ($p=8.4e-5$) met a Bonferroni level
401 ($p<0.05/177=0.00028$) for a test for an association with urinary symptoms in the GERA cohort
402 (**Table S4, S6, S14**). In variants identified in the joint meta-analysis, none met a Bonferroni level
403 of significance ($p<0.05/110=0.00045$).

404

405 **PSA variant associations with prostate volume**

406 We found that 31 of the 407 PSA variants tested demonstrated some evidence of an
407 association with prostate volume in the PASS cohort. rs182464120 on chromosome 19 was
408 strongly associated ($p=2.0e-11$), rs12344353 on chromosome 9 was associated at a Bonferroni
409 level ($p=5.3e-5 < 0.05/407=0.00012$), and 29 other variants were associated at a nominal
410 significance level ($p<0.05$) (**Table S15**).

411

412 **Associations with *KLK3* plasma pQTL**

413 We annotated the 447 variants from the joint GWAS meta-analysis using recently published
414 plasma pQTL association results for *KLK3* from the UKB Pharma Proteomics Project using the
415 Olink Explore platform;³⁰ 409 had corresponding pQTL associations in the UKB. In European
416 ancestry individuals ($n=46,214$), GWAS and *KLK3* pQTL effects were highly correlated ($R=0.85$,
417 $p=3.7e-117$) (**Figure S6**). Eleven variants were associated with relative *KLK3* abundance at
418 $p<0.05/409$, and, as expected, the strongest two associations were in *KLK3* (rs17632542,
419 rs61752561) (**Table S16**). Among African ancestry individuals ($n=1,065$), we observed an
420 attenuated correlation with effects on *KLK3* abundance ($R=0.14$, $p=0.0034$), although none of
421 the individual pQTL associations reached statistical significance.

422

423 **Associations with eGenes**

424 In our sc-RNA-seq data analysis, we found that each of the eGenes for PSA-associated variants
425 is expressed across prostate cells. This is especially true in prostate luminal epithelial cells
426 (which produce PSA) and is expected if the genes modify PSA levels (**Table S17**). **Figure S7**
427 shows expression of the eQTL genes across multiple prostate tissue cell types, including luminal
428 cells of the prostate epithelium and its precursor cells (e.g., basal epithelial cells of prostate;
429 expression sorted by *KLK3*). Percentile expression of the eQTL-associated genes was significantly
430 higher in luminal cells than all other prostate cell types ($P=0.0006$), suggesting these genes are
431 more active in this cell type than other prostate cells (**Figure S8**) and supporting the hypothesis
432 that these eQTL genes are involved in PSA expression.

433

434 **Discussion**

435 Our GWAS detected 448 genome-wide significant variants associated with PSA levels, of which
436 295 were novel (184 in discovery and 111 in a meta-analysis), nearly quadrupling the total
437 number of associated variants. The variance explained by genome-wide PRSs ranged from
438 11.6%-16.9% in men of European ancestry, 5.5%-9.5% in men of African ancestry, 13.5%-
439 18.6% in Hispanics/Latinos, and 8.6%-15.3% in the East Asian ancestry group. We also
440 observed a decline in PRS predictive performance with increasing age, particularly at the oldest
441 ages. The majority of newly identified variants were uniquely associated with PSA and not PCa.

442

443 Our discovery cohort included more African ancestry individuals than any prior study of PSA
444 genetics. Of the eight genome-wide significant variants that were identified in the discovery
445 phase in African ancestry, only two were sufficiently common to be assessed in European
446 ancestry. Of those two, the association between rs1203888 (*LINC00261*) and PSA levels was
447 unique to the African ancestry population. These eight variants generally failed to meet
448 Bonferroni significance in our replication cohort, although the sample size was small (3,509
449 individuals of African ancestry); the variant rs18447639 in the *AR* gene was closest to
450 replicating. Androgen receptor (*AR*) signaling is required for normal prostate development and
451 function but is hijacked during carcinogenesis.³¹ Because prostate tumor growth and
452 progression depend on *AR* signaling, androgen deprivation therapy remains a frontline
453 treatment for progressing PCa, and the inhibition of *AR* activity may delay progression.³²

454
455 A total of 10.8% of novel discovery and replication variants were prostate tissue eQTLs, and
456 another 49.7% were eQTLs in other tissues. In addition, 16 discovery variants and five meta-
457 analysis variants had predicted deleterious regulatory effects. Putative deleterious genes
458 included: *AOC1*, which regulates histamine metabolism and sensitivity to non-steroidal anti-
459 inflammatory drugs^{33,34}; *MPZL2*, which is involved in thymus development and T-cell maturation;
460 and *ZC3HC1*, a regulator of cell cycle progression and established susceptibility locus for
461 coronary artery disease^{35,36}. We also observed an association with PSA levels for the deltaF508
462 mutation in *CFTR* that causes cystic fibrosis, which is accompanied by infertility in 97% of
463 affected males³⁷ and has been linked to obstructive azoospermia (ClinVar³⁸ accession
464 SCV001860325). We detected another signal with possible links to male fertility, rs372203682
465 in *LMTK2*, a gene implicated in spermatogenesis³⁹ that interacts with *AR* and inhibits its
466 transcriptional activity⁴⁰.

467
468 In SELECT, the variance in PSA levels explained by our independently associated GWAS
469 variants was ~1% larger than previously explained²⁰ in European and ~3% higher in African
470 ancestry individuals. The variance explained in SELECT and PCPT was substantially less than
471 that in GERA, even though we evaluated only variants from our discovery cohort (which did not
472 include GERA). This may be due in part to the studies' selection criteria, as individuals in
473 SELECT and PCPT were required to have PSA ≤ 3 ng/mL²³ and ≤ 4 ng/mL²⁴, respectively, at
474 baseline. However, in AOU, which did not have this selection criteria, variance explained for
475 European ancestry men was at most 0.5% higher than SELECT, and thus also lower than
476 GERA. For African ancestry men in AOU, variance explained was 2-3% lower than in SELECT,
477 suggesting that differences in performance may be attributed to factors other than preferential
478 selection for low baseline PSA. We also investigated whether BPH may contribute to variability
479 in PRSs performance. The estimated variance explained was <0.5% higher when excluding
480 men with a BPH diagnosis. By BPH, we mean a clinical diagnosis rather than presence of BPH.
481 Most patients evaluated for potential PCa have evidence of BPH, which can result in elevated
482 PSA levels^{41,42}. These findings highlight the need to evaluate genetically adjusted PSA in a
483 wider range of clinical settings, as well as the challenges with curating out-of-sample cohorts
484 with clinical data sufficient for such evaluations.

485

486 The performance of PRS constructed using weights derived from the multi-ancestry meta-
487 analysis typically matched or surpassed the performance of PRSs based on ancestry-specific
488 weights. As expected, genome-wide PRS-CSx generally achieved 1-6% higher explained
489 variance than the PRSs limited to mJAM genome-wide significant variants. However, the
490 improvement in performance observed for PRS-CSx was not equal across populations. The
491 largest increase was observed for Hispanic/Latino men, followed by European ancestry men
492 (generally similar to Hispanic/Latino men), followed by Asian ancestry men. To our knowledge,
493 this is the first time out of sample PRS performance was assessed in a Hispanic/Latino
494 population. Relative to the fine-mapped PRS, the degree of improvement was smallest for
495 African ancestry. This may be due to a number of factors. First, PRS-CSx uses a single
496 hyperparameter to couple posterior effect sizes across ancestry groups, which may be
497 insufficient to capture different correlation structures among populations. Second, HapMap3
498 variants used by PRS-CSx do not tag genetic variation equally well across ancestries. Fine-
499 mapping PRS methods do not limit to this set of tagging SNPs and may be more likely to
500 capture population-specific variants. Third, the choice of linkage disequilibrium (LD) reference
501 panels has slightly different implications for the two PRS approaches. PRS-CSx relies on LD
502 reference panels for estimating joint SNP effect sizes, while fine-mapping requires LD
503 information for identifying independent variants from summary statistics. mJAM advances other
504 fine-mapping approaches by incorporating population-specific LD, which is more accurate than
505 using a single population as the LD reference²¹ or only making use of the largest ancestry
506 group. While PRS-CSx provides more flexibility to accommodate different genetic architectures,
507 it may be more sensitive to the choice of LD reference panels and mismatches in LD structure
508 between PRS training and testing populations, especially without a separate dataset for
509 parameter tuning.

510
511 We found that genetically adjusting PSA levels reduced unnecessary biopsies in controls, albeit
512 less so than in previous work²⁰ in the same GERA population. It is likely that our previous study
513 overestimated reclassification in controls because there was partial overlap between the GWAS
514 meta-analysis used to train the PRS used for adjustment - GERA was included - and the
515 population in which we undertook genetic adjustment. In the present study, we performed
516 genetic adjustment using a PRS trained on a large GWAS that did not include GERA. We also
517 saw an increase in magnitude in genetically-adjusted midlife PSA association with PCa in most
518 GERA groups, although CIs overlapped for all, and while our previous study²⁰ did not see any
519 benefit in African ancestry, here we saw an increase.

520
521 Our investigation had several limitations. Relative to prior studies of PSA genetics, the discovery
522 and replication cohorts included here substantially increased the number of men from diverse
523 populations. While both were very large (N~300K and ~100K men total), the replication cohorts
524 had disproportionately smaller African ancestry (discovery N ~58K and replication N ~3.5K) and
525 Hispanic/Latino populations (N~24K and ~3K). Going forward, our PSA Consortium will continue
526 to seek new study populations with both genotypic and phenotypic data that represent diverse
527 participants. Nevertheless, for African ancestry, 43% of variants met a nominal replication
528 threshold, many more than the 5% that would be expected by chance. We also suspect that we

529 had limited power to detect effect size heterogeneity, especially since variants that exhibited
530 significant heterogeneity were mostly known variants in strongly associated regions. Another
531 limitation is that GERA biopsy reclassification may have been specific to Kaiser Permanente
532 clinical guidelines, as previously discussed²⁰. In addition, while we did our best to restrict
533 relevant analyses to PCa-free individuals, some individuals likely had undetected PCa⁴³.
534 However, the number was unlikely to be large enough to materially impact our results because
535 our study population was relatively young; the average age among men in the MVP (which
536 comprised a large majority of our discovery study population, N~286K) was 58 years for men of
537 European ancestry, 52 years for men of African ancestry, and 54 years for Hispanic/Latino men
538 or Asian ancestry men. Further, the PSA PRS_{CSx} explained increasing variability in PSA levels
539 for individuals of younger ages. Most novel PSA-associated variants were not associated with
540 PCa, and those that were may have been due to screening bias, as previously shown²⁰. The
541 lack of BPH information in most of our cohorts was an additional limitation, but most novel
542 variants associated with PSA levels were not associated with BPH in others' work on UKB
543 European ancestry individuals²⁹, and the variance explained by PRSs in SELECT was affected
544 by <0.5% in participants with BPH. We were unable to account for prostate volume, a strong
545 predictor of PSA levels⁴⁴. Finally, we note that our GWAS and resulting PRSs were developed
546 for total PSA. Future work should work toward capturing genetic factors that are specific to
547 constituents of total PSA.

548
549 In summary, we undertook a large-scale, multi-ancestry study with over three times the sample
550 size of previous work,²⁰ expanded our understanding of the genetic basis of PSA levels and our
551 potential to improve the accuracy of PSA genetic adjustment across ancestries. Using an
552 ancestrally diverse study population, we detected hundreds of novel variants associated with
553 PSA levels that were largely independent of PCa and BPH. These findings explain additional
554 variation in PSA levels, especially among men of African ancestry, who suffer the highest
555 morbidity and mortality due to PCa, as well as among Hispanic/Latino men. This highlights the
556 importance of studying diverse populations to enable novel discoveries and construct PRS that
557 will perform equally across ancestry groups. Taken together, our work moved us closer to
558 leveraging genetic information to personalize and substantially improved our understanding of
559 the genetic basis of PSA levels and of genetic adjustment of PSA levels across individuals of
560 diverse ancestries.

561 562 **Methods**

563 ***Discovery participants and phenotype measurements***

564 Our primary analyses included 296,754 men from seven cohorts that had not previously been
565 analyzed in studies of PSA genetics. These are described briefly below; additional details,
566 including array, ancestry, imputation reference panels, sample sizes, number of variants, and
567 standard filters applied are described in **Tables S1-S3**. To ensure participants had a functional
568 prostate unaffected by surgery or radiation and to exclude individuals at a high risk of
569 undiagnosed PCa⁴⁵, participants were restricted to men with no history of PCa or surgical
570 resections of the prostate, and at least one PSA measurement between 0.01 and 10ng/mL.
571 Analyses were based on each individual's earliest recorded PSA level. For descriptive statistics,

572 meta-analysis of PSA medians from each cohort was done with the weighted median of
573 medians method in the R v4.2.3⁴⁶ package *metamediation* v1.0.0⁴⁷. Sub-populations were
574 defined by self-identified race/ethnicity and/or genetically-inferred ancestry, depending on the
575 cohort.

576
577 *African American Prostate Consortium (AAPC)*. The AAPC is comprised of African ancestry
578 studies with PCa phenotyping.²⁷

579
580 *Mount Sinai BioMe® Biobank (BioMe)*. BioMe is a longitudinal cohort linked to Epic electronic
581 health records (EHRs)⁴⁸. Individuals were European ancestry, Hispanic/Latino, and African
582 ancestry.

583
584 *Chicago Multiethnic Prevention and Surveillance Study (COMPASS)*. COMPASS is a
585 longitudinal study of Chicagoans with >11,000 participants currently enrolled (82% African
586 American).⁴⁹ PSA data has been described previously⁵⁰.

587
588 *Men of African Descent and Carcinoma of the Prostate (MADCaP)*. MADCaP is a consortium of
589 epidemiologic studies addressing the high PCa burden in African ancestry men.^{51,52}

590
591 *Multiethnic Cohort (MEC)*. MEC is a prospective cohort study that enrolled >215,000 Hawaii/Los
592 Angeles residents ages 45-75 years between 1993-1996.^{53,54}

593
594 *Million Veteran Program (MVP)*. MVP is a multi-ancestry cohort recruited nationwide.
595 Information is obtained from EHRs, including inpatient International Classification of Diseases
596 (ICD)-9 codes, Current Procedural Terminology (CPT) procedure codes, clinical laboratory
597 measurements, and reports of diagnostic imaging modalities⁵⁵. Sub-populations were created
598 using the harmonized ancestry and race/ethnicity (HARE) method.⁵⁶

599
600 *Southern Community Cohort Study (SCCS)*. SCCS is a prospective cohort study that recruited
601 85,000 predominantly African ancestry adults from community health centers in the
602 southeastern United States. This study included only men of African ancestry.⁵⁷

603 604 **Replication cohorts**

605 Genome-wide significant variants identified in the discovery cohort were tested for replication in
606 the previous largest GWAS of PSA levels, which included 95,768 men (85,824 European
607 ancestry, 89.6%)²⁰, using a Bonferroni corrected α level. In addition, previously-identified
608 genome-wide significant variants²⁰ were tested for replication in our independent discovery
609 cohort. Statistical tests throughout were two-sided.

610 611 **Additional PRS evaluation cohorts**

612 For our discovery cohort results, we evaluated PSA PRS performance and reclassification in
613 individuals from the GERA cohort (also in the replication cohort, out-of-sample for the discovery

614 cohort (n=35,322; 28,503 European; 2,716 Latino; 2,518 East Asian; and 1,585 African
615 American)).
616
617 Additional out-of-sample cohorts for (both the discovery analysis and the joint meta-analysis of
618 discovery and replication) PRS assessment was done in genotyped individuals from the PCPT²⁴
619 (n=5,725 European) and SELECT²³ (n=25,366; 22,173 European; 1,763 African
620 American/European; 1,173 African American; and 257 East Asian) and All of Us (AOU;
621 n=17,512; 11,922 European; 2,469 African American; 1,783 other; 1,336 Hispanic/Latino)²⁵,
622 which have been previously described. Briefly, PCPT and SELECT began as randomized,
623 placebo-controlled, double-blind clinical trials of finasteride and selenium and vitamin E,
624 respectively, and both enrolled men ≥ 55 y. Individuals in SELECT and PCPT were required to
625 have PSA ≤ 3 ng/mL²³ and ≤ 4 ng/mL²⁴, respectively, at baseline. The National Institutes of Health
626 (NIH) AOU cohort is committed to including groups that have been historically underrepresented
627 in research²⁵. From AOU, we selected individuals with PSA > 0.01 between the ages of 40 and
628 90, with short-read whole-genome sequencing (WGS) data and no survey or EHR
629 conditions/observations reflecting a history of PCa. The median PSA measurement we used
630 was required to be ≤ 10 ng/mL. PRSs were calculated with the WGS data subset to variants with
631 population-specific allele frequency $\geq 1\%$ or a population-specific allele count > 100 for any
632 genetic ancestry. Genetic ancestry was determined using a random forest classifier trained on
633 the principal component (PC) space of the Human Genome Diversity Project and 1000
634 Genomes Project (KGP)⁵⁸.

635 636 ***Ethical considerations***

637 Informed consent was obtained from all study participants. AAPC was approved by their IRB.
638 The ethics review board of the Program for the Protection of Human Subjects of Mount Sinai
639 School of Medicine approved BioMe (#HSD09-00030, #07-0529 0001 02 ME). The University of
640 Chicago Biological Sciences Division IRB Committee A (#IRB12-1660) approved COMPASS.
641 Local and national IRBs approved MadCAP. MEC was approved by their IRB. The VA Central
642 institutional review board (IRB) approved the MVP. The IRBs at Vanderbilt University and
643 Meharry Medical College approved SCCS. Vanderbilt University Medical Center IRB approved
644 BioVU. GERA was approved by the Kaiser Permanente Northern California IRB and the
645 University of California, San Francisco. A local ethics committee approved the Malmo Diet and
646 Cancer Study (MDCS). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening
647 Trial was approved by the IRBs at each participating center and the National Cancer Institute,
648 and the informed consent document allows data use for cancer and other adult disease
649 investigations; we used publicly posted summary statistics, for which no IRB is required. The
650 research was conducted with approved access to UKB data (#14105).

651 652 ***Genotype quality control and imputation***

653 Study subjects were genotyped using conventional GWAS arrays (**Table S1**). Genotypes were
654 then imputed using imputation servers⁵⁹, Minimac3⁶⁰, or IMPUTE2⁶¹. The vast majority of
655 studies imputed to the KGP phase 3 reference panel⁶², with one sub-study imputing to KGP
656 phase 1 just for the X chromosome⁶³ and another imputing to the TOPMed reference panel⁵⁹.
657 Since all but two studies (>95% of participants) used genome build 37, we lifted over the
658 assembly of those from build 38 using triple-liftOver⁶⁴ v133 (2022-05-20), an extension of
659 LiftOver⁶⁵ that accounts for regions that are inverted between builds.

660
661 Standard genotype and individual-level QC procedures were implemented in each ancestry
662 group in each participating study. Specific study protocols are delineated in **Table S1**, with
663 additional QC steps and details in **Table S2**. Unless information was unavailable or a filter did
664 not make sense for a particular group, variants were retained if their imputation quality score
665 was ≥ 0.3 , their MAF was $\geq 0.5\%$ if the sample size was ≥ 1000 and $\geq 5\%$ otherwise, their Hardy-
666 Weinberg equilibrium (HWE) was $\geq 1e-8$, they were mapped in build 37, and they had an MAF
667 difference ≤ 0.2 compared to KGP populations (full details in **Table S3**). For the cohorts that
668 meta-analyzed sub-cohorts (e.g., the three small African ancestry sub-cohorts within the SCCS
669 African ancestry group; **Table S2**), we also required that variants be present in all sub-cohorts
670 (necessary for multi-ancestry analysis method limitations, although this removed only a very
671 small number of variants, **Table S3**). Finally, we excluded variants if they were present in only
672 one study with $n < 2,000$.

673 674 **Association analyses**

675 GWAS within each ancestry group in each study were undertaken using linear regression of log
676 PSA on additive genotypes, and, when using multiple measurements, the long-term average
677 residual by individual⁶⁶. The minimum set of covariates included age at PSA measurement and
678 genetic ancestry PCs. If available, GWAS also adjusted for batch/array, body mass index, and
679 smoking status (**Table S1**). Meta-analyses of each ancestry group and across the overall
680 discovery cohort were conducted using inverse-variance weighted fixed effects models using a
681 custom patched version of METAL v2011-03-25 that prevents numerical precision loss (lines
682 633 and 635 of "Main.cpp" modified to the number 15 to output 15 digits precision)⁶⁷. We also
683 assessed heterogeneity with Cochran's Q across the four ancestry groups.

684
685 To identify independently associated genome-wide significant ($p \leq 5e-8$) variants with
686 computational efficiency, we first formed clumps of genome-wide significant variants such that
687 all clumps were $\geq 10\text{Mb}$ apart and independent of one another; specifically, the top variant was
688 chosen, genome-wide significant variants $\leq 10\text{Mb}$ from any variant in the clump were added to
689 the clump, the process was iterated until a final clump was formed, and then the process was
690 repeated to form more clumps (i.e., clumps were created such that there was no additional

691 genome-wide significant variant $\leq 10\text{Mb}$). Within each clump, we used mJAM v2022-08-05²¹,
692 which uses population-specific LD reference panels for each contributing cohort and ancestry
693 group to model the correlation among variants, with an $r^2 < 0.01$ threshold in all ancestry groups.
694 Genotypes utilizing the appropriate GERA cohort group (European, Hispanic/Latino, African
695 American, and East Asian) served as references⁶⁸.

696
697 To maximize discovery efforts, we combined our discovery cohort ($n=296,754$) with our
698 replication cohort ($n=95,768$), for a total of 392,522 individuals.

699
700 Associations were considered novel if they had low LD from all previously-reported variants²⁰.
701 Specifically, we required $r^2 < 0.01$ in all four ancestry groups, again using GERA as LD reference.

702 **Annotation**

703 Variants were annotated using FUMA⁶⁹. We first prioritized genes that included a significant
704 prostate eQTL from GTEx v8 (www.gtexportal.org). We then prioritized other significant eQTLs
705 and finally by closest gene. Deleteriousness of mutations was determined by CADD scores; a
706 recommended cutoff to identify potentially pathogenic variants of scores ≥ 15 has been
707 suggested (the median of splice site changes and non-synonymous variants from CADD v1.0;
708 corresponds to the top 3.2% of variants)⁷⁰. Gene functions were characterized with RefSeq⁷¹.
709 Circos plots were generated using Circos v0.69-6⁷².

710 **Medication sensitivity analysis**

711
712 Some of our study participants may have taken medications that can affect PSA levels. In
713 particular, 5-alpha reductase inhibitors and testosterone can impact PSA levels^{73,74}. We
714 assessed the use of these medications among 26,669 men of European ancestry in the UKB
715 with at least one PSA measurement. Men with a prescription for at least one of the two
716 medications prior to PSA measurement were considered users. Ten percent of the men were
717 prescribed 5-alpha reductase inhibitors and 0.56% testosterone. We also controlled for potential
718 confounding by alpha blocker use.

719 **Out-of-sample PRS variance explained**

720
721 We calculated PRSs to assess the overall PSA variance explained by genetics, and to adjust
722 PSA measurements for PSA genetics. All PRS results are shown only in independent cohorts
723 (i.e., training dataset completely independent of testing dataset), such that assessments of
724 performance are unbiased. Nonparametric bootstrap percentile CIs for variance explained were
725 calculated using 1000 replicates.

726
727
728 We used two sets of individuals to construct the PRSs. First, we constructed PRSs from our
729 discovery cohorts to allow assessment in GERA, PCPT, SELECT, and AoU. Second, we
730 constructed PRSs from the meta-analysis of discovery and replication cohorts (which included
731 GERA), with assessment in PCPT, SELECT, and AoU only. For GERA we included results

732 using first and multiple measurements; for PCPT and SELECT we include results using the first
733 measurement.

734
735 We also used two sets of variants to calculate the PRSs in each of the two sets of individuals.
736 We first utilized the independent genome-wide significant variants discovered in our analyses
737 (one for discovery and one for the meta-analysis of discovery and replication). Second, we
738 constructed a genome-wide score using PRS-CSx v2023-08-10⁷⁵, which was implemented
739 utilizing GWAS summary statistics, the 1,287,078 HapMap3 variants as an LD reference that
740 had an imputation quality >0.9 in SELECT, using a global shrinkage parameter of $\phi=0.0001$
741 (which performed well in our previous work²⁰), and variants with imputation quality ≥ 0.9 . Since
742 PRS-CSx only considers autosomes, independent genome-wide significant X chromosome
743 variants were included (and produced a negligible increase in performance). The final scores
744 were calculated by summing the effect size times the (probabilistic) number of alleles at each
745 locus with PLINK v2.00a3.7LM⁷⁶.

746
747 We also assessed the variance explained by the discovery PRS-CSx within age intervals in
748 GERA; we looked only in GERA to have an out-of-sample estimate from discovery and a large
749 enough sample size at each age. An individual could be in multiple bins, but using just the first
750 measurement of that individual per age bin.

751 752 ***Fur PSA for PCa screening in GERA***

753 We adjusted PSA levels as has been described previously²⁰. Briefly, PSA values for individual i
754 were adjusted by $PSA_i^{adj} = PSA_i / a_i$, where a_i is a personalized adjustment factor derived from
755 our PRS, as: $a_i = \exp(PRS_i) / \exp(\text{mean}(PRS))$. Here we estimated the mean(PRS) value within
756 each group in the GERA cohort. We then evaluated the potential utility to alter biopsy referrals
757 using age-specific PSA thresholds used within the Kaiser system (40-49y=2.5, 50-59y=3.5, 60-
758 69=4.5, and 70-79=6.5 ng/ml⁷⁷), evaluating net reclassification in cases and controls²⁰.

759
760 We also tested for associations of our PSA^{adj} with Gleason score (≤ 6 , 7, and ≥ 8) using
761 multinomial logistic regression with the R package nnet v7.3.18⁷⁸.

762
763 To assess whether there was variability in PSA adjustment across PSA levels, we first binned
764 PSA values (with smaller ranges in lower values where there was more data). Within each bin,
765 we computed $PSA - PSA_{adjusted}$, and then computed the median and IQR of these values. The
766 median and IQR were then plotted at the center point of each bin by adding them to the identity
767 line.

768 769 ***Impact of genetically-adjusted midlife PSA on overall and aggressive PCa prediction***

770 We next investigated the impact of genetically adjusting PSA on the prediction of overall and
771 aggressive PCa in the GERA cohort (3540 cases [1,028 aggressive, Gleason ≥ 7], 21,702

772 controls). We constructed a midlife PSA²⁶ based on each participant's median PSA between 50-
773 60y, with cases restricted to measurements ≥ 1 y before diagnosis. Genetic PSA adjustment was
774 performed as in the previous section. Associations between PSA or genetically adjusted log
775 PSA and PCa risk were assessed using logistic regression for overall PCa cases vs controls
776 and for aggressive cases vs. controls, adjusting for covariates in Table S1. AUC was estimated
777 using 10-fold repeated cross-validation (10 repeats) with caret v6.0.90⁷⁹.

778

779 ***Bias-corrected PCa estimates***

780 PCa associations in individuals with European ancestry in the PRACTICAL consortium²⁷ were
781 adjusted for screening bias²⁸, using estimates previously derived²⁰: $\beta'_{\text{Cancer}} = \beta_{\text{Cancer}} - b\beta_{\text{PSA}}$,
782 $SE'_{\text{Cancer}} = (\text{SE}_{\text{Cancer}}^2 + b^2\text{SE}_{\text{PSA}}^2 + \text{SE}_b^2\beta_{\text{PSA}} + \text{SE}_b^2\text{SE}_{\text{PSA}}^2)$, where SE is the standard error, and
783 estimates were $b=1.144$, and $\text{SE}_b=2.909\text{e-}4$.

784

785 ***Associations with urinary symptom variants***

786 We evaluated whether the novel PSA variants were associated with urinary symptoms in the
787 GERA cohort. Individuals in this cohort completed the first 6 (of 7) questions from the American
788 Urological Association Symptom Index (AUA-SI)⁸⁰ with 5-point Likert scale responses. The
789 questions asked about incomplete emptying, frequency, intermittency, urgency, weak stream,
790 and straining (**Table S13**). The one missing question from the AUA-SI regarded nocturia. We
791 calculated total scores as the sum of the questions, giving each individual a value ranging from
792 6-30. The score was dichotomized at <7 , ≥ 7 to differentiate men with little or no BPH
793 ($N=12,846$) from those with moderate or severe BPH ($N=15,480$). We then assessed the
794 association between the PSA variants and the urinary symptom score.

795

796 ***Prostate volume analysis***

797 We evaluated associations between PSA variants and prostate volume in patients on active
798 surveillance (AS) enrolled in the Canary Prostate Active Surveillance Study (PASS). Between
799 2008-2017, PASS prospectively enrolled 1455 patients with clinically localized PCa (cT1-cT2
800 and Gleason Grade 1-2) to undergo AS at one of 10 national sites⁸¹. Prostate volume was
801 measured at diagnosis, with a median measurement of 43.0cc (IQR=31.0-57.5). The median
802 age at diagnosis was 63 years (IQR=58-67), and 85% of the PASS cohort self-reported as
803 European ancestry. Genotyping was conducted in 1,220 participants⁸². We assessed potential
804 associations between the 407 PSA variants that we successfully imputed in PASS and prostate
805 volume using mixed models with fixed effects for genetic variants, age at diagnosis, and 10
806 PCs, and a random effect for a genetic relationship matrix.

807

808 ***Associations with eGenes***

809 We used single cell RNA sequencing (scRNA-seq) data to assess whether the eGenes for PSA-
810 associated variants (Table S7) are expressed in secretory prostate cell types, particularly
811 luminal epithelial cells, more so than other prostate cell types. For these analyses, we used data
812 from the Chan Zuckerberg Cell by Gene census v2023-12-15⁸³.

813

814 **Data availability**

815 Summary statistics (from the discovery analysis and the final meta-analysis) will be made
816 available in the NHGRI-EBI GWAS Catalog ([https://www.ebi.ac.uk/gwas/downloads/summary-](https://www.ebi.ac.uk/gwas/downloads/summary-statistics)
817 [statistics](https://www.ebi.ac.uk/gwas/downloads/summary-statistics)). PRS weights (PRS₃₁₈, PRS₄₄₇, PRS_{CSx,disc}, PRS_{CSx,joint}) will be made available in the
818 PGS catalog (<https://www.pgscatalog.org/>). To protect individuals' privacy, complete GERA data
819 are available upon approved applications to the Kaiser Permanente Research Bank Portal
820 (<https://researchbank.kaiserpermanente.org/for-researchers>). UKB data are available in the
821 UKB cloud-based Research Analysis Platform (<https://www.ukbiobank.ac.uk>). GTEx data were
822 obtained from the GTEx portal (www.gtexportal.org) and can be obtained from dbGaP
823 Accession phs000424.v8.p2.

824

825 **Code availability**

826 Genome-wide association analysis were conducted using PLINK v2.0a3.7LM ([http://www.cog-](http://www.cog-genomics.org/plink/2.0/)
827 [genomics.org/plink/2.0/](http://www.cog-genomics.org/plink/2.0/)). Meta-analysis were conducted with a custom-patched METAL v2011-
828 03-25 (https://genome.sph.umich.edu/wiki/METAL_Documentation) that prevents numerical
829 precision loss (lines 633 and 635 of "Main.cpp" modified to the number 15 to output 15 digits
830 precision"), and with MJAM v2022-08-05 (<https://github.com/USCbiostats/hJAM/R>). Imputation
831 was done via imputation servers (<https://imputationserver.sph.umich.edu>,
832 <https://imputation.biodatacatalyst.nih.gov>), Minimac3
833 (<https://genome.sph.umich.edu/wiki/Minimac3>), and IMPUTE2
834 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html). Analysis were also conducted in R,
835 including v4.2.0 (<https://cran.r-project.org/>). FUMA was used for annotation
836 (<https://fuma.ctglab.nl>). Circos plots were generated using Circos v0.69-6
837 (<https://fuma.ctglab.nl>). The genome-wide PRS was conducted with PRS-CSx v2023-08-10
838 (<https://github.com/getian107/PRScsx>).

839

840 **Acknowledgements**

841 We thank the participants who generously agreed to participate in each cohort. This research is
842 based in part on data from the Million Veteran Program (MVP), Office of Research and
843 Development, Veterans Health Administration, and was supported by the MVP017 Exemplar
844 Cancer Project. This research was conducted using the UKB resource under application
845 number 14105. In addition, the All of Us Research Program would not be possible without the
846 partnership of its participants.

847

848 **Funding**

849 The Precision PSA study is supported by funding from the National Institutes of Health (NIH)
850 National Cancer Institute (NCI) under award number R01CA241410 (PI: JSW) and
851 U01CA261339 (MPI: JSW). LK is supported by funding from the National Cancer Institute

852 (R00CA246076). REG is supported by a Young Investigator Award from the Prostate Cancer
853 Foundation. HL is supported in part by NIH/NCI by a Cancer Center Support Grant to Memorial
854 Sloan Kettering Cancer Center (P30 CA008748, PI: Vickers, S), U01-CA266535 (PI: Carlsson,
855 S), R01-CA244948 (PI: RJK), and Swedish Cancer Society (Cancerfonden 20 1354 PJF; PI:
856 HL). This work was supported by research grants from the NIH National Institute of General
857 Medical Sciences (NIGMS) under award number R01GM130791 (PI: JDM); the computational
858 resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine
859 at Mount Sinai; the Office of Research Infrastructure of the National Institutes of Health under
860 award number S10OD026880 and NIH/NCI funding (R01CA175491, R01CA244948; PI: RJK);
861 the National Cancer Institute of the National Institutes of Health (UM1CA182883, PI: CM
862 Tangen/IM Thompson; U10CA37429, PI: CD Blanke). MADCaP was supported by
863 U01CA184374 (PI: TR). COMPASS was supported by P30CA014599. Support for GERA
864 participant enrollment, survey completion, and biospecimen collection for RPGEH was provided
865 by the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison
866 Medical Foundation, and Kaiser Permanente national and regional benefit programs. GERA
867 genotyping was funded by National Institute on Aging and NIH Common Fund (grant RC2 AG-
868 036607 to Cathy Schaeffer and Neil Risch). The All of Us Research Program is supported by
869 the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2
870 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2
871 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #:
872 AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research
873 Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176;
874 Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement:
875 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2
876 OD025315; 1 OT2 OD025337; 1 OT2 OD025276.

877
878 The content is solely the responsibility of the authors and does not necessarily represent the
879 official views of the National Institutes of Health. The funders had no role in study design, data
880 collection and analysis, the decision to publish, or preparation of the manuscript.


881
882 **Conflict of Interest**

883 JSW and CLC are non-employee co-founders of Avail Bio. HL is named on a patent for intact
884 PSA assays and a patent for a statistical method to detect prostate cancer that is licensed to
885 and commercialized by OPKO Health. HL receives royalties from sales of the test and has stock
886 in OPKO Health. REG consults for Hunton Andrews Kurth LLP on subject matter unrelated to
887 this study.

888
889


890 **Figures and Tables**

891 **Figure 1. Flowchart describing the Precision PSA project analysis workflow and ancestry**
 892 **compositions of the discovery, replication, and joint meta-analysis cohorts.** The discovery
 893 GWAS analysis revealed 318 genome-wide significant ($p < 5e-8$) SNPs associated with PSA
 894 levels, of which 184 were novel. The joint analysis (consisting of the discovery and replication
 895 cohorts) revealed 447 genome-wide significant SNPs associated with PSA levels, of which an
 896 additional 111 were novel. Both discovery and joint GWAS results were used to develop PRSs
 897 for PSA, which were then evaluated in GERA (when out-of-sample), PCPT, and SELECT.




898
 899
 900

901 **Figure 2. Circos plot showing PSA GWAS significant variants by chromosome from the**
902 **discovery cohort.** Concentric tracks are colored based on results from individual ancestries,
903 with gray indicating results from the overall discovery meta-analysis. The top 100,000 GWAS
904 SNPs (with the smallest p-values) per ancestry are shown as points; larger circled points
905 indicate the 318 genome-wide significant variants ($p < 5e-8$; 184 of which were novel) from the
906 overall discovery analysis in all ancestries. SNP density in 10Mbp bins from the overall analysis
907 is shown as a heatmap above the overall track. The outermost ring displays genes associated
908 with novel discovery PSA SNPs.




909
910
911

912 **Figure 3. Manhattan plot showing results from the joint multi-ancestry meta-analysis of**
913 **the discovery (n=296,754) and replication (n=95,768) studies.** Only genome-wide significant
914 associations ($p < 5e-8$) are plotted. The joint analysis detected 447 independent genome-wide
915 significant PSA-associated SNPs. These included 111 novel variants that were conditionally
916 independent from previous findings and the discovery only analyses in each study alone (
917 indicated by the circles). Gene labels are given for variants with $CADD > 15$ and/or variants that
918 are prostate tissue eQTLs.




919
920
921

922 **Figure 4. Plot of the relationship between minor allele frequency and estimated effect**
923 **sizes for PSA GWAS significant variants.** Each point represents one of the 447 independent
924 genome-wide significant SNPs identified in our mJAM multi-ancestry GWAS joint meta-analysis.
925 The SNP effect sizes are expressed in $\ln(\text{PSA})$ per minor allele. The curves indicate the
926 hypothetical detectable SNP effect sizes for a given minor allele frequency, assuming statistical
927 power of 80%, $\alpha=5e-8$ (genome-wide significant), and the sample size of each of our
928 populations here (297,166 European ancestry, $N=61,745$ African ancestry, 6,967 Asian
929 ancestry, 26,644 Hispanic).



930
931
932


933 **Figure 5. Variance in PSA levels explained by PRSs.** We constructed PRSs for PSA from our
 934 discovery cohorts to allow assessment in GERA and our PRS validation cohorts (PCPT and
 935 SELECT). We also constructed PRSs from the joint meta-analysis of discovery and replication
 936 cohorts, with assessment in our validation cohorts. The PRSs were based on the multi-ancestry
 937 identified conditionally independent genome-wide significant variants using mJAM and on a
 938 multi-ancestry genome-wide score using PRS-CSx. The genome-wide score generally
 939 performed better than the genome-wide significant score. The variance explained by genome-
 940 wide PRSs **(A)** was up to 16.9% in Europeans, 18.6% in Hispanics/Latinos, 9.5% in Africans,
 941 and **(B)** decreased as age increased.




942
 943
 944

945 **Figure 6. Biopsy reclassification with genetically-adjusted PSA.** PSA levels were adjusted
 946 using the PRS-CSx estimate from the out-of-sample discovery cohort, assessed in GERA using
 947 age-specific cutoffs in **(A)** Europeans and **(B)** African Americans (see **Methods**). GERA Latinos
 948 and East Asians are shown in **Figure S3**.

A



B



950 **References**

951

- 952 1. Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal
953 vesicle protein. *J Clin Invest* **76**, 1899–1903 (1985).
- 954 2. Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer:
955 prediction, detection and monitoring. *Nat Rev Cancer* **8**, 268–278 (2008).
- 956 3. Balk, S. P., Ko, Y.-J. & Bubley, G. J. Biology of prostate-specific antigen. *J Clin Oncol* **21**,
957 383–391 (2003).
- 958 4. Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer:
959 prediction, detection and monitoring. *Nat Rev Cancer* **8**, 268–278 (2008).
- 960 5. Pinsky, P. F. *et al.* Prostate volume and prostate-specific antigen levels in men enrolled in a
961 large screening trial. *Urology* **68**, 352–356 (2006).
- 962 6. Lee, S. E. *et al.* Relationship of prostate-specific antigen and prostate volume in Korean
963 men with biopsy-proven benign prostatic hyperplasia. *Urology* **71**, 395–398 (2008).
- 964 7. Grubb, R. L. *et al.* Serum prostate-specific antigen hemodilution among obese men
965 undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening
966 Trial. *Cancer Epidemiol Biomarkers Prev* **18**, 748–751 (2009).
- 967 8. Harrison, S. *et al.* Systematic review and meta-analysis of the associations between body
968 mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.
969 *Cancer Causes Control* **31**, 431–449 (2020).
- 970 9. Jemal, A. *et al.* Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF
971 Screening Recommendations. *JAMA* **314**, 2054–2061 (2015).
- 972 10. Gulati, R., Inoue, L. Y. T., Gore, J. L., Katcher, J. & Etzioni, R. Individualized estimates of
973 overdiagnosis in screen-detected prostate cancer. *J Natl Cancer Inst* **106**, djt367 (2014).
- 974 11. Sammon, J. D. *et al.* Prostate-Specific Antigen Screening After 2012 US Preventive
975 Services Task Force Recommendations. *JAMA* **314**, 2077–2079 (2015).
- 976 12. Hugosson, J. *et al.* A 16-yr Follow-up of the European Randomized study of Screening for
977 Prostate Cancer. *Eur Urol* **76**, 43–51 (2019).
- 978 13. Sandhu, G. S. & Andriole, G. L. Overdiagnosis of Prostate Cancer. *J Natl Cancer Inst*
979 *Monogr* **2012**, 146–151 (2012).
- 980 14. Frånlund, M. *et al.* Results from 22 years of Followup in the Göteborg Randomized
981 Population-Based Prostate Cancer Screening Trial. *J Urol* **208**, 292–300 (2022).
- 982 15. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive
983 Services Task Force Recommendation Statement. *JAMA* **319**, 1901–1913 (2018).
- 984 16. Bell, N. *et al.* Recommendations on screening for prostate cancer with the prostate-specific
985 antigen test. *CMAJ* **186**, 1225–1234 (2014).
- 986 17. Tikkinen, K. A. O. *et al.* Prostate cancer screening with prostate-specific antigen (PSA) test:
987 a clinical practice guideline. *BMJ* **362**, k3581 (2018).
- 988 18. Bansal, A. *et al.* Heritability of prostate-specific antigen and relationship with zonal prostate
989 volumes in aging twins. *J Clin Endocrinol Metab* **85**, 1272–1276 (2000).
- 990 19. Pilia, G. *et al.* Heritability of Cardiovascular and Personality Traits in 6,148 Sardinians. *PLoS*
991 *Genet* **2**, e132 (2006).
- 992 20. Kachuri, L. *et al.* Genetically adjusted PSA levels for prostate cancer screening. *Nat Med*
993 **29**, 1412–1423 (2023).
- 994 21. Shen, J. *et al.* Fine-mapping and credible set construction using a multi-population joint
995 analysis of marginal summary statistics. doi:<https://doi.org/10.1101/2022.12.22.521659>.
- 996 22. Kerem, B. S. *et al.* DNA marker haplotype association with pancreatic sufficiency in cystic
997 fibrosis. *Am J Hum Genet* **44**, 827–834 (1989).
- 998 23. Lippman, S. M. *et al.* Effect of selenium and vitamin E on risk of prostate cancer and other
999 cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* **301**, 39–51

- 1000 (2009).
- 1001 24. Thompson, I. M. *et al.* Assessing prostate cancer risk: results from the Prostate Cancer
1002 Prevention Trial. *J Natl Cancer Inst* **98**, 529–534 (2006).
- 1003 25. Mayo, K. R. *et al.* The All of Us Data and Research Center: Creating a Secure, Scalable,
1004 and Sustainable Ecosystem for Biomedical Research. *Annu Rev Biomed Data Sci* **6**, 443–
1005 464 (2023).
- 1006 26. Preston, M. A. *et al.* Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal
1007 Prostate Cancer. *J Clin Oncol* **34**, 2705–2711 (2016).
- 1008 27. Conti, D. V. *et al.* Trans-ancestry genome-wide association meta-analysis of prostate cancer
1009 identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet* **53**, 65–75
1010 (2021).
- 1011 28. Dudbridge, F. *et al.* Adjustment for index event bias in genome-wide association studies of
1012 subsequent events. *Nat Commun* **10**, 1561 (2019).
- 1013 29. Jiang, L., Zheng, Z., Fang, H. & Yang, J. A generalized linear mixed model association tool
1014 for biobank-scale data. *Nat Genet* **53**, 1616–1621 (2021).
- 1015 30. Eldjarn, G. H. *et al.* Large-scale plasma proteomics comparisons through genetics and
1016 disease associations. *Nature* **622**, 348–358 (2023).
- 1017 31. Kim, J. & Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. *J*
1018 *Cell Biochem* **93**, 233–241 (2004).
- 1019 32. Heinlein, C. A. & Chang, C. Androgen Receptor in Prostate Cancer. *Endocrine Reviews* **25**,
1020 276–308 (2004).
- 1021 33. Agúndez, J. A. G. *et al.* The diamine oxidase gene is associated with hypersensitivity
1022 response to non-steroidal anti-inflammatory drugs. *PLoS One* **7**, e47571 (2012).
- 1023 34. Amo, G. *et al.* FCERI and Histamine Metabolism Gene Variability in Selective Responders
1024 to NSAIDs. *Front Pharmacol* **7**, 353 (2016).
- 1025 35. Miller, C. L. *et al.* Integrative functional genomics identifies regulatory mechanisms at
1026 coronary artery disease loci. *Nat Commun* **7**, 12092 (2016).
- 1027 36. Linseman, T. *et al.* Functional Validation of a Common Nonsynonymous Coding Variant in
1028 ZC3HC1 Associated With Protection From Coronary Artery Disease. *Circ Cardiovasc Genet*
1029 **10**, e001498 (2017).
- 1030 37. Cuppens, H. & Cassiman, J.-J. CFTR mutations and polymorphisms in male infertility. *Int J*
1031 *Androl* **27**, 251–256 (2004).
- 1032 38. Landrum, M. J. *et al.* ClinVar: improvements to accessing data. *Nucleic Acids Research* **48**,
1033 D835–D844 (2020).
- 1034 39. Kawa, S. *et al.* Azoospermia in mice with targeted disruption of the Brek/Lmtk2 (brain-
1035 enriched kinase/lemur tyrosine kinase 2) gene. *Proc Natl Acad Sci U S A* **103**, 19344–
1036 19349 (2006).
- 1037 40. Cruz, D. F., Farinha, C. M. & Swiatecka-Urban, A. Unraveling the Function of Lemur
1038 Tyrosine Kinase 2 Network. *Frontiers in Pharmacology* **10**, (2019).
- 1039 41. Bostwick, D. G. *et al.* The association of benign prostatic hyperplasia and cancer of the
1040 prostate. *Cancer* **70**, 291–301 (1992).
- 1041 42. Ørsted, D. D. & Bojesen, S. E. The link between benign prostatic hyperplasia and prostate
1042 cancer. *Nat Rev Urol* **10**, 49–54 (2013).
- 1043 43. Thompson, I. M. *et al.* Prevalence of prostate cancer among men with a prostate-specific
1044 antigen level < or =4.0 ng per milliliter. *N Engl J Med* **350**, 2239–2246 (2004).
- 1045 44. Coric, J., Mujic, J., Kucukalic, E. & Ler, D. Prostate-Specific Antigen (PSA) and Prostate
1046 Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men. *Open*
1047 *Biochem J* **9**, 34–36 (2015).
- 1048 45. D’Amico, A. V. Risk-based management of prostate cancer. *N Engl J Med* **365**, 169–171
1049 (2011).

- 1050 46. R Core Team. R: A language and environment for statistical computing. (2012).
1051 47. McGrath, S., Zhao, X., Qin, Z. Z., Steele, R. & Benedetti, A. One-sample aggregate data
1052 meta-analysis of medians. *Statistics in Medicine* **38**, 969–984 (2019).
1053 48. Tayo, B. O. *et al.* Genetic background of patients from a university medical center in
1054 Manhattan: implications for personalized medicine. *PLoS One* **6**, e19166 (2011).
1055 49. Aschebrook-Kilfoy, B. *et al.* Cohort profile: the ChicagO Multiethnic Prevention and
1056 Surveillance Study (COMPASS). *BMJ Open* **10**, e038481 (2020).
1057 50. Press, D. J. *et al.* Tobacco and marijuana use and their association with serum prostate-
1058 specific antigen levels among African American men in Chicago. *Prev Med Rep* **20**, 101174
1059 (2020).
1060 51. Andrews, C. *et al.* Development, Evaluation, and Implementation of a Pan-African Cancer
1061 Research Network: Men of African Descent and Carcinoma of the Prostate. *J Glob Oncol* **4**,
1062 1–14 (2018).
1063 52. Harlemon, M. *et al.* A Custom Genotyping Array Reveals Population-Level Heterogeneity for
1064 the Genetic Risks of Prostate Cancer and Other Cancers in Africa. *Cancer Res* **80**, 2956–
1065 2966 (2020).
1066 53. Kolonel, L. N., Altshuler, D. & Henderson, B. E. The multiethnic cohort study: exploring
1067 genes, lifestyle and cancer risk. *Nat Rev Cancer* **4**, 519–527 (2004).
1068 54. Kolonel, L. N. *et al.* A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.
1069 *Am. J. Epidemiol.* **151**, 346–357 (2000).
1070 55. Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences
1071 on health and disease. *J Clin Epidemiol* **70**, 214–223 (2016).
1072 56. Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-
1073 wide Association Studies. *The American Journal of Human Genetics* **105**, 763–772 (2019).
1074 57. Signorello, L. B. *et al.* Southern community cohort study: establishing a cohort to investigate
1075 health disparities. *J Natl Med Assoc* **97**, 972–979 (2005).
1076 58. Venner, E. *et al.* The frequency of pathogenic variation in the All of Us cohort reveals
1077 ancestry-driven disparity. Preprint at <https://doi.org/10.1101/2022.12.19.22283658> (2022).
1078 59. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program | Nature.
1079 <https://www.nature.com/articles/s41586-021-03205-y>.
1080 60. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**,
1081 1284–1287 (2016).
1082 61. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate
1083 genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet*
1084 **44**, 955–959 (2012).
1085 62. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
1086 *Nature* **526**, 68–74 (2015).
1087 63. Consortium, T. 1000 G. P. A map of human genome variation from population-scale
1088 sequencing. *Nature* **467**, 1061–1073 (2010).
1089 64. Sheng, X. *et al.* Inverted genomic regions between reference genome builds in humans
1090 impact imputation accuracy and decrease the power of association testing. *HGG Adv* **4**,
1091 100159 (2023).
1092 65. Karolchik, D. *et al.* The UCSC Genome Browser database: 2014 update. *Nucl. Acids Res.*
1093 **42**, D764–D770 (2014).
1094 66. Ganesh, S. K. *et al.* Effects of Long-Term Averaging of Quantitative Blood Pressure Traits
1095 on the Detection of Genetic Associations. *The American Journal of Human Genetics* **95**, 49–
1096 65 (2014).
1097 67. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
1098 genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
1099 68. Hoffmann, T. J. *et al.* Genome-wide association study of prostate-specific antigen levels

- 1100 identifies novel loci independent of prostate cancer. *Nat Commun* **8**, 14248 (2017).
- 1101 69. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
1102 annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 1103 70. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human
1104 genetic variants. *Nat Genet* **46**, 310–315 (2014).
- 1105 71. O’Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status,
1106 taxonomic expansion, and functional annotation. *Nucleic Acids Res* **44**, D733–745 (2016).
- 1107 72. Krzywinski, M. *et al.* Circos: an information aesthetic for comparative genomics. *Genome*
1108 *Res* **19**, 1639–1645 (2009).
- 1109 73. Gerstenbluth, R. E., Maniam, P. N., Corty, E. W. & Seftel, A. D. Prostate-specific antigen
1110 changes in hypogonadal men treated with testosterone replacement. *J Androl* **23**, 922–926
1111 (2002).
- 1112 74. Guess, H. A., Heyse, J. F. & Gormley, G. J. The effect of finasteride on prostate-specific
1113 antigen in men with benign prostatic hyperplasia. *Prostate* **22**, 31–37 (1993).
- 1114 75. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet*
1115 **54**, 573–580 (2022).
- 1116 76. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
1117 datasets. *GigaScience* **4**, (2015).
- 1118 77. Oesterling, J. E. *et al.* Serum prostate-specific antigen in a community-based population of
1119 healthy men. Establishment of age-specific reference ranges. *JAMA* **270**, 860–864 (1993).
- 1120 78. W. N. Ripley & B. D. Ripley. *Modern Applied Statistics with S*. (Springer, New York, NY,
1121 USA, 2002).
- 1122 79. Kuhn, M. Building Predictive Models in R Using the caret Package. *Journal of Statistical*
1123 *Software* **28**, 1–26 (2008).
- 1124 80. Barry, M. J. *et al.* The American Urological Association Symptom Index for Benign Prostatic
1125 Hyperplasia. *J Urol* **197**, S189–S197 (2017).
- 1126 81. Newcomb, L. F. *et al.* Canary Prostate Active Surveillance Study: design of a multi-
1127 institutional active surveillance cohort and biorepository. *Urology* **75**, 407–413 (2010).
- 1128 82. Jiang, Y. *et al.* Genetic Factors Associated with Prostate Cancer Conversion from Active
1129 Surveillance to Treatment. *HGG Adv* **3**, 100070 (2022).
- 1130 83. Program, C. S.-C. B. *et al.* CZ CELLxGENE Discover: A single-cell data platform for
1131 scalable exploration, analysis and modeling of aggregated data. 2023.10.30.563174
1132 Preprint at <https://doi.org/10.1101/2023.10.30.563174> (2023).
- 1133
- 1134